Friday, September 16, 2011

Sheep help NovaBay target sinusitis

NovaBay Pharmaceuticals Inc. is counting on sheep sinuses to shepherd one of its experimental drugs into flocks of patients and investors.
NVC-422 is one of the Emeryville drug developer’s (AMEX: NBY) so-called Aganocide compounds, designed to kill bacteria quickly and effectively but without the bacteria building up resistance over time. The compound is being studied in everything from the skin infection impetigo to urinary catheter blockage to eye care, though Novartis’ Alcon eye care unit returned rights to the drug this summer.
But recent findings from an Australian study could cause NovaBay to put more attention on sinusitis.

No comments:

Post a Comment